Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03304964 Active, not recruiting - Healthy Clinical Trials

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Start date: July 21, 2017
Phase: Phase 1
Study type: Interventional

This is a single-center, phase I study consisting of 2 parts. The first part is a multiple ascending dose (MAD) part with a randomized, double-blind, placebo-controlled design in 3 treatment groups of 8 subjects (6 active; 2 placebo). The second part is a food effect (FE) part with a randomized, open-label, 2-period, 2-way crossover, single dose design in 8 subjects.

NCT ID: NCT03295578 Active, not recruiting - Healthy Clinical Trials

Blood Glucose, Cognition and Wellbeing @ Work

Start date: October 2, 2017
Phase: N/A
Study type: Interventional

This randomized controlled pilot study has as a main aim to investigate the relationship between glucose and cognition and wellbeing, as well as food intake in an at-work setting. Additionally, the continuous glucose data collected in the study will be used to investigate the inter- and intraindividual variability in glucose response to foods/meal in a real-life setting. Finally, the study aims to determine if self-monitoring and feedback about food intake and health stimulate individuals to make healthier choices. This study will have two groups, the feedback group and the control group. The study will consist of two self-monitoring periods of two weeks. In between these two self-monitoring periods, the participants in the feedback group will be given feedback on their measurement data. The control group will not get any feedback.

NCT ID: NCT03279393 Active, not recruiting - Healthy Clinical Trials

PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

Start date: March 17, 2017
Phase: Early Phase 1
Study type: Interventional

Project 3 of the PPG grant "Stress and Atherosclerotic Plaque Macrophages A Systems Biology Approach," funded by the NHLBI, examines the relationship between psychosocial stress and atherosclerotic inflammation, cell proliferation and burden using novel PET/MRI. Individuals with post-traumatic stress disorder, trauma controls and healthy controls will be recruited into a two center clinical study. The study team will use functional MRI to examine the relationship between activation of fear circuits in the brain and relate these data to hematopoietic system activation, and vascular inflammation measured by FDG-PET, and atherosclerotic burden measured by MRI.

NCT ID: NCT03262597 Active, not recruiting - Healthy Clinical Trials

"Beverage Hydration Index" of Commercial Therapeutic Beverages

Start date: February 17, 2017
Phase: N/A
Study type: Interventional

The "beverage hydration index" (BHI) assesses the hydration potential of any consumable fluid relative to water. The BHI is a relatively new metric. Our purpose was to assess the BHI of beverages never previously tested, including an amino acid-based oral rehydration solution (AA-ORS), a glucose-containing ORS (G-ORS) and a sports drink (SD) compared to water (control).

NCT ID: NCT03259490 Active, not recruiting - Healthy Clinical Trials

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Start date: August 31, 2017
Phase: Phase 1
Study type: Interventional

To establish the bioequivalence of one fixed dose combination (FDC) tablet of empagliflozin/linagliptin/metformin extended release (XR) versus the free combination of empagliflozin tablet, linagliptin tablet, and metformin XR tablets administered as a single dose under fed conditions

NCT ID: NCT03258372 Active, not recruiting - Healthy Clinical Trials

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Start date: August 16, 2017
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single center, fixed sequence, open label, drug-drug interaction study of the effect of multiple doses of rifampin 600 mg daily, a strong CYP3A inducer, on the exposure of mifepristone at 2 dose levels.

NCT ID: NCT03248609 Active, not recruiting - Healthy Clinical Trials

Glycemic Index of Table Grape Varietals

Start date: July 31, 2017
Phase: N/A
Study type: Interventional

Investigate the postprandial glycemic responses of healthy individuals when consuming commercially available table grape varietals or grape juice, compared to a standard amount of glucose.

NCT ID: NCT03244501 Active, not recruiting - Healthy Clinical Trials

Transcranial Static Magnetic Field Stimulation of Frontal Cortex

Start date: August 8, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to see if a new brain stimulation technique, static magnetic field stimulation (tSMS), which involves holding a static neodymium magnet over the scalp, can influence normal rhythms of brain activity.

NCT ID: NCT03228446 Active, not recruiting - Healthy Clinical Trials

The Effects of Attentional Filter Training on Working Memory

DIIN
Start date: September 26, 2012
Phase: N/A
Study type: Interventional

The investigators are interested in how attentional filter training/ distractor inhibition training could influence cognitive functions like working memory, executive control, problem solving, decision making and attentional control.

NCT ID: NCT03210805 Active, not recruiting - Healthy Clinical Trials

Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation

STC
Start date: January 9, 2017
Phase: N/A
Study type: Interventional

Investigate the in vivo effects of n-3 PUFA supplementation on inflammation, gene expression and epigenetic signatures. Ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) collected pre and post n-3 supplementation and measurement of it's effect on inflammation, gene expression and epigenetic signatures.